RxSight, Inc. (RXST): Results of Operations and Financial Condition
RxSight, Inc. (RXST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rxst-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 RXSIGHT, INC. REPORTS SECOND QUARTER 2026 RESULTS AND PROVIDES UPDATE ON 2026 OUTLOOK Aliso Viejo, Calif. – August 5, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, a
How this was made
The 30-second read
Why it matters
Q2 results show revenue growth supported by collaboration revenue, but product sales declined and gross margin excluding collaboration fell due to inventory-related costs. The company withdrew 2026 guidance and plans to resume formal guidance in early 2027, likely shifting valuation from near-term execution to longer-cycle platform and commercial execution.
Market read
Traders get a fresh quarterly datapoint plus a direct expectation reset via guidance withdrawal, alongside leadership and product-platform updates.
What to watch
The release does not quantify Alcon collaboration milestones timing or installed-base adoption metrics; traders may be over-weighting the guidance withdrawal without seeing demand indicators.
Background
RxSight is a cataract surgery IOL company with a light-adjustable lens platform and a strategic collaboration with Alcon.
Ticker impact
RxSight reported Q2 2026 revenue of $33.7M, product sales down 19% YoY, and withdrew 2026 guidance alongside an Alcon collaboration update.
Likely choppy trading around the guidance withdrawal and margin/volume details, with upside sensitivity to any early-2027 guidance reinstatement.
Guidance withdrawal is a direct expectation reset, while the quarter shows declining product sales and mixed gross margin drivers (inventory costs vs collaboration revenue).
Market effects
Could influence sentiment toward ophthalmic medtech and cataract IOL adoption narratives, especially around adjustable IOL platforms.
Primarily US small-cap medtech sentiment; limited direct regional spillover indicated.
Alcon collaboration ties RxSight to a global ophthalmology commercial partner, but no additional global milestones were quantified beyond the stated upfront and milestones.
Counterpoint
The guidance withdrawal may be operational flexibility rather than deterioration, and collaboration revenue plus a next-gen platform could improve adoption and margins later.
Key entities
- companyRxSight, Inc.
NASDAQ-listed ophthalmic medical device company reporting Q2 2026 results and withdrawing 2026 guidance.
- partnerAlcon
Strategic collaboration partner providing collaboration revenue and co-development/commercialization of light-adjustable presbyopia-correcting IOLs.
- executiveAziz Mottiwala
Appointed President and CEO, and stated a comprehensive business review with guidance withdrawal for flexibility.
